Human Recombinant IGF-BP6 (from (BTI-Tn-5B1-4) Hi-5 Insect cells)
Supplier: PEPROTECH INC.Total Ratings: 0
Avg. Ratings: 0.0 out of 5
IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP6, which specifically inhibits IGF-II actions, is produced by bone cells and is the major IGF-BP present in cerebrospinal fluid. IGF-BP6 has been shown to inhibit IGF-II-dependent cancers such as neuroblastoma, colon cancer and rhabdomyosarcoma. Recombinant Human IGF-BP6 has a calculated mass of 22.3 kDa and consists of 213 amino acid residues, including the IGF-BP domain and thyroglobulin type-I domain. Recombinant Human IGF-BP6 migrates at an apparent molecular weight of approximately 23.0-30.0 kDa by SDS-PAGE analysis under non-reducing conditions.
Ordering information: For research use only. Not for use in diagnostic or therapeutic procedures.
Learn more

About VWR
Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...